STOCK TITAN

Absci Corporation - ABSI STOCK NEWS

Welcome to our dedicated page for Absci Corporation news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci Corporation stock.

Absci Corporation (Nasdaq: ABSI) is a leading company that leverages the power of artificial intelligence to drive the next generation of drug discovery and development. Based in Vancouver, WA, Absci combines advanced AI technology with scalable wet lab processes, aiming to revolutionize the speed and efficacy of creating novel biologics.

Absci's core business revolves around its Integrated Drug Creation™ platform, which offers a unified approach to biologic drug discovery and cell line development. By optimizing multiple drug characteristics simultaneously, this platform accelerates the timeline from concept to clinic while increasing the probability of success in therapeutic development. The company is uniquely positioned to screen billions of cells per week, enabling rapid transformation from AI-designed antibodies to wet lab-validated candidates in as little as six weeks.

Recent achievements include the presentation of positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program. The company has initiated IND-enabling studies and plans to submit an Investigational New Drug application in the first quarter of 2025. Additionally, Absci has forged strategic partnerships, such as a high-profile collaboration with AstraZeneca aimed at advancing an AI-designed oncology candidate, potentially valued at up to $247 million.

Financially, Absci has strengthened its balance sheet through successful public offerings, raising approximately $86 million in gross proceeds. This financial boost ensures the company has the resources needed to advance its internal programs and continue investment in its groundbreaking platform.

Absci's innovative approach and commitment to leveraging AI for drug discovery have not only enhanced its internal pipeline but also attracted significant industry partnerships. The company’s vision of delivering breakthrough therapeutics at the click of a button continues to drive its mission forward, promising better and faster solutions for patients worldwide.

Rhea-AI Summary
Absci Corporation (ABSI) announced a public offering of 16.7 million shares of common stock at $4.50 per share, expecting to raise approximately $75.2 million. The proceeds will fund internal asset programs, AI technology, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) has announced a public offering of $75.0 million of its common stock, with an option for underwriters to purchase an additional $11.25 million. The proceeds will fund internal asset programs, investment in its Integrated Drug Creation™ platform, and general corporate purposes. Morgan Stanley and TD Cowen are the joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
-
Rhea-AI Summary
Absci Corporation announces the initiation of IND-enabling studies for ABS-101, a promising anti-TL1A antibody, designed using its generative AI model. The company aims to submit an IND in Q1 2025 and commence Phase 1 trials soon after, showcasing the potential for faster drug discovery using AI technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
AI
Rhea-AI Summary
Absci Corporation (ABSI) announces its participation in several upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and KeyBanc Capital Markets Emerging Technology Summit. The company will engage in fireside chats to discuss its AI-based drug creation technology. Interested parties can access live and archived webcasts of these events on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
conferences
-
Rhea-AI Summary
Absci (Nasdaq: ABSI) appoints Professor Sir Menelas 'Mene' Pangalos, a distinguished biopharmaceutical executive, to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board. Sir Pangalos, with over 25 years of experience in drug discovery and development, joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. His appointment follows the recent addition of former Phillips CEO Frans van Houten to the Board. Absci’s recent collaborations with AstraZeneca and Almirall underscore its commitment to leveraging AI to bring impactful drugs to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
management
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) announced positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program, at the 42nd Annual J.P. Morgan Healthcare Conference. The company's generative AI platform designed over 50 antibody leads with subnanomolar affinity, selecting three potential candidates for the ABS-101 program. The preclinical studies demonstrated properties consistent with a potentially superior product profile, supporting the program’s potential to create an efficacious candidate conducive to subcutaneous dosing. Absci expects to initiate Investigational New Drug application (IND) enabling studies for ABS-101 in February 2024, and submit an IND in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.47%
Tags
conferences clinical trial
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to participate in 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
conferences
-
Rhea-AI Summary
Absci (Nasdaq: ABSI) and PrecisionLife collaborate to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The partnership aims to create a pipeline of novel biotherapeutics for chronic diseases. Absci achieves its 2023 outlook of ten new Active Programs signed for the year through this collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
partnership AI
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) collaborates with AstraZeneca to develop an AI-designed antibody for oncology. The collaboration combines Absci's generative AI technology with AstraZeneca's expertise, aiming to accelerate the discovery of a potential new cancer treatment candidate. The agreement includes an upfront commitment, R&D funding, milestone payments, and royalties on product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
AI

FAQ

What is the current stock price of Absci Corporation (ABSI)?

The current stock price of Absci Corporation (ABSI) is $2.99 as of December 20, 2024.

What is the market cap of Absci Corporation (ABSI)?

The market cap of Absci Corporation (ABSI) is approximately 336.0M.

What does Absci Corporation specialize in?

Absci specializes in using artificial intelligence and scalable wet lab technologies to accelerate the creation of novel biologics for therapeutic use.

What is Absci's Integrated Drug Creation™ platform?

The Integrated Drug Creation™ platform optimizes multiple drug characteristics simultaneously, speeding up the transition from concept to clinic and increasing the probability of success in development.

What are some of Absci's recent achievements?

Recent achievements include presenting positive preclinical data for ABS-101, initiating IND-enabling studies, and partnering with AstraZeneca for an AI-designed oncology candidate.

How has Absci strengthened its financial position?

Absci has strengthened its financial position through public offerings, raising approximately $86 million in gross proceeds to fund its internal programs and platform investments.

What is the significance of Absci's collaboration with AstraZeneca?

The collaboration with AstraZeneca combines Absci's AI drug creation platform with AstraZeneca's oncology expertise, aiming to advance a new AI-designed cancer treatment candidate valued at up to $247 million.

Where are Absci's main operational facilities located?

Absci's headquarters is in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.

What is the timeline for ABS-101's clinical trials?

Absci expects to submit an IND for ABS-101 in the first quarter of 2025 and initiate Phase 1 clinical studies shortly thereafter.

How does Absci's AI technology contribute to drug discovery?

Absci's AI technology enables rapid screening and design of drug candidates, optimizing multiple characteristics important to both development and therapeutic benefit, thus accelerating the overall drug discovery process.

What are some of the internal programs Absci is focusing on?

Absci is focusing on several internal programs, including ABS-101 for anti-TL1A, ABS-201 for dermatology, and ABS-301 for immuno-oncology, alongside advancing additional internal asset programs.

How can interested parties stay updated on Absci's developments?

Interested parties can stay updated by visiting Absci's website and investor relations page, where they routinely post investor presentations, SEC filings, press releases, and webcasts.

Absci Corporation

Nasdaq:ABSI

ABSI Rankings

ABSI Stock Data

335.95M
90.93M
20.09%
62.57%
10.45%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
VANCOUVER